A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
Completed · Phase 3 · NCT04660643
Conditions: Obesity, Overweight
At a glance
- Research payments reported, 2025
- $2,500
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 783
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Tirzepatide (drug), Placebo (other)
- Dates
- Started 2021-03-29; completion 2023-05-18
- Results posted
- Yes
This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss. The study had two phases: a lead-in phase in which all participants took tirzepatide and a treatment phase in which participants either continued tirzepatide or switched to placebo. The study lasted about 2 years (25 visits).
From ClinicalTrials.gov, last updated 2024-05-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $2,500 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Clinical Trials of Texas Inc $2,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.